revenu declin due drop biosimilar product sale tp
maintain hold rate downgrad tp
tp base forward price-to-earnings multipl
estim non-gaap ep
provid upsid potenti
downgrad tp due declin revenu
also led declin stock price
estim base follow factor strong
revenu biopharma group recent acquisit
approv drug declin upjohn revenu
expect revenu rang
consid anticip impact pend
format consum healthcar jv pend array
acquisit complet therachon acquisit expect
declin revenu growth
pfizer revenu decreas
oper growth driven volum driven
growth biopharma busi includ continu growth
key brand ibranc eliqui xeljanz well
emerg market growth partial off-set
impact gener biosimilar competit product
lost market exclus well expect
declin upjohn revenu china
basic ep increas dilut ep
increas basic ep increas
dilut ep increas
compani name inc tickerpfestock ratingholdunchangedindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu upjohn segment declin
decreas
reflect oper declin oper
decreas emerg market primarili driven lipitor
norvasc
lyrica revenu declin
declin total revenu
 declin declin
declin due
lower volum reflect wholesal destock advanc
anticip multi-sourc gener competit
expect begin juli instead began juli
global gener specialti
combin upjohn creat new global
pharmaceut compani term agreement
structur all-stock revers morri trust
transact sharehold would
sharehold would combin new compani
announc posit preliminari result proof-of-
concept phase studi
pneumococc conjug vaccin candid
investig prevent invas diseas otiti
media infant
current price-to-earnings ratio fallen
due declin stock price
quarter price-to-earnings fallen
averag price-to-earnings expect forward price-to-earnings
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend ex-dividend last split factor new per last split date jul inform pfizer inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur merger oper total oper oper interest incom incom provis incom net incom continu net incom discontinu prefer net incom avail common weight averag share estim annual actual annual actual quarterli inc octob
equival short term invest trade asset secur total st invest receivablesaccount receiv receiv total receiv current assetsinventori defer tax asset current restrict current asset total current asset long-term assetsgross properti plant equip accumul depreci properti plant equip long-term invest goodwil intang defer tax asset long-term asset total asset current liabilitiesaccount payabl accru expens short-term borrow current portion lt debt current incom tax payabl unearn revenu current current liabil total current liabil long-term liabilitieslong-term debt unearn revenu non-curr pension post-retir benefit def tax liabil non-curr non-curr liabil total liabil prefer equitypref stock convert total prefer equiti common equitycommon stock addit paid capit retain earn treasuri stock incom common equiti stockhold equityminor interest total equiti liabil equitytot liabil equiti balanc sheet itemsactu annual actual quarterli inc octob
net cash provid oper activ compar
decreas net cash provid oper activ reflect time receipt custom
payment vendor ordinari cours busi partial off-set increas net incom
decreas benefit plan contribut
net cash provid invest activ compar
decreas attribut decreas net proce gener sale invest
cash need
net cash use financ activ compar
decreas due issuanc long-term debt correspond
issuanc debt net proce rais short-term borrow
compar net proce partial off-set higher purchas common stock
higher repay long-term debt lower proce exercis stock
option
incom oper activitiesdepreci amort amort goodwil intang depreci amort total loss sale asset asset write-down restruc cost stock-bas compens oper activ account receiv chang inventori chang account payabl chang net oper asset oper invest activitiescapit expenditur acquisit sale purchas intang asset invest market equiti securt invest activ invest financ activitiesshort term debt issu long-term debt issu total debt issu short term debt repaid long-term debt repaid total debt repaid common stock repurchas common stock common prefer stock dividend paid financ activ financ equivalentsforeign exchang rate adjust adjust net chang inc octob
pfizer result favor impact lower tax rate higher
oper revenu lower acquisition-rel cost fewer share
outstand result unfavor impact lower net gain equiti
secur foreign exchang impact
pfizer revenu decreas compar
oper growth partial
off-set unfavor impact foreign exchang quarter
pfizer revenu increas
compar total intern revenu decreas
compar
emerg market revenu decreas
compar reflect unfavor impact
foreign exchang partial off-set oper increas
oper increas emerg market driven ibranc eliqui
prevenar biopharma segment
sale decreas compar
sale revenu
compar decreas due favor impact
foreign exchang favor impact hedg activ
inter-company inventori
si expens declin compar
si expens revenu
compar decreas due
favor impact foreign exchang
lower advertis promot field forc expens develop
market primarili relat lyrica us
si expens partial off-set addit invest across
sever product primarili xeljanz chantix/champix
support vyndaqel launch addit invest china
decreas
compar
compar
 expens increas compar
 expens revenu
compar amort intang asset decreas
compar
amort revenu compar
deduct compar incom
oper incom declin
compar effect tax rate
compar adjust effect tax rate
compar
net incom increas compar
basic ep increas
compar dilut ep increas
compar
pfizer revenu remain rel flat compar
reflect unfavor impact foreign exchang
oper increas
pfizer revenu increas
compar total intern revenu remain flat
compar
emerg market revenu increas compar
reflect oper increas foreign
exchang unfavor impact emerg market revenu
oper increas emerg market driven prevenar
ibranc eliqui pfizer biopharma segment lipitor norvasc
celebrex upjohn segment
compar
compar
sale decreas
compar
flat
compar
sale decreas compar
sale revenu compar
decreas due favor impact foreign
exchang favor impact hedg activ inter-company
inventori partial off-set unfavor chang product mix
si expens declin compar
si expens revenu
compar decreas due
favor impact foreign exchang
lower advertis promot field forc expens develop
market primarili relat lyrica us
non-recurr special one-tim bonu paid virtual
colleagu exclud execut aggreg
partial off-set
addit invest across sever key product primarili
xeljanz chantix/champix support vyndaqel launch
addit invest china across key brand non-recurr
favor true-up healthcar reform expens
 expens remain flat compar
 expens revenu flat compar
increas due
increas spend pfizer inflamm immunolog
diseas portfolio due sever phase program invest gene
increas invest toward build new capabl drive
amort intang asset decreas
compar amort revenu
compar
deduct compar incom
oper incom declin
compar effect tax rate
compar
net incom increas compar
basic ep increas
compar dilut ep increas
compar
oper three busi biopharmaceut group upjohn
consum healthcar biopharma group contribut revenu
quarter upjohn segment contribut revenu consum
healthcar unit contribut revenu quarter
net incom increas
compar
biopharmaceut group biopharma science-bas innov
medicin busi includ busi unit oncolog inflamm
immunolog diseas hospit vaccin intern medicin
increas
increas
new hospit busi unit commerci global portfolio steril
inject anti-infect medicin includ pfizer contract
manufactur oper centreon also incorpor
biosimilar portfolio oncolog inflamm immunolog busi
unit certain legaci establish product intern medicin
busi unit busi unit commit deliv breakthrough
biopharma revenu increas compar
increas compar
total revenu increas
compar increas
compar total intern revenu decreas
compar increas
compar
compar
total revenu decreas compar
decreas primarili reflect lower govern
purchas pediatr indic well continu declin
revenu adult indic due high initi captur rate
elig popul follow success launch
total revenu decreas
compar decreas due continu
declin revenu adult indic us due
aforement declin catch opportun adult indic
compar
oper growth
increas
increas
intern oper growth increas
increas increas primarili
due higher volum result increas shipment associ
gavi vaccin allianc higher volum reflect continu uptak
follow launch china partial off-set non-recurr
volum associ adult nation immun program
total revenu ibranc increas
compar increas
compar
total revenu increas
compar increas
compar
total intern revenu increas
compar increas
compar
world-wide oper growth reflect continu strong uptak
develop europ japan well certain emerg market
growth us primarili driven
cyclin-depend kinas class share growth ibranc continu
class share leadership approv metastat breast cancer
total revenu
ibranc increas
increas
total revenu xeljanz increas
compar increas
compar
total revenu increas
compar increas
compar revenu
increas compar
increas compar
growth driven volum growth launch
uc indic indic well
continu growth ra indic partial off-set higher rebat
unfavor channel mix
oper growth intern driven continu uptak
ra indic develop europ emerg market japan
canada well recent launch uc indic certain
eliqui jointli develop commerci
bm pfizer fund develop cost
depend studi profit loss share equal global
basi except certain countri commerci eliqui
pay bm compens base percentag net sale
total revenu eliqui increas
compar increas
compar
total revenu
xeljanz increas
increas
total revenu
eliqui increas
increas
total revenu increas
compar increas
compar total intern revenu
increas compar
increas compar
world-wide oper growth driven continu increas
adopt non-valvular atrial fibril well oral anti-coagul
enbrel outsid canada
total revenu enbrel decreas
compar decreas
compar world-wide oper
declin due on-going biosimilar competit develop
europ market expect continu well unfavor
impact time govern purchas certain emerg market
xtandi develop commerci collabor
astella two compani share equal gross profit loss
relat net sale xtandi subject certain except
astella also share equal xtandi commerci cost attribut
 market
astella also share certain develop collabor
expens receiv tier royalti percentag
total revenu
eliqui us
increas
increas
compar
total revenu
enbrel decreas
compar
total revenu xtandi increas
compar increas
compar growth
driven increas demand xtandi metastat mcrpc non-
higher patient assist program pap util
total revenu chantix/champix decreas
compar increas
compar total revenu
 increas compar
increas
compar total intern revenu declin
compar
declin compar
growth due increas volum improv patient
access posit price impact oper declin intern
driven gener entri south korea canada
total revenu sutent decreas
compar decreas
compar world-wide oper
declin revenu reflect continu eros result increas
competit us key develop market partial off-set
growth certain emerg market
total revenu
xtandi increas
increas
total revenu
sutent decreas
compar
total revenu
sulperazon increas
compar
total revenu decreas
compar decreas
compar total intern revenu
decreas compar
decreas compar
total revenu
decreas
compar
total revenu sulperazon increas
compar increas
compar intern
oper growth due increas demand china
total revenu premarin decreas
compar decreas
compar world-wide oper
declin driven competit pressur
total revenu decreas
compar decreas
compar total intern revenu
declin compar
decreas compar
total revenu inflectra/remsima decreas
compar decreas
compar
total revenu
xalkori declin
decreas
compar
decreas due continu volum growth certain channel
us well certain develop market europ canada
off-set price pressur global well competit pressur
total revenu increas
compar increas
compar total intern revenu
declin compar
decreas compar
total revenu xalkori declin
compar decreas
compar declin result
eros due competit develop europ us
partial off-set growth certain emerg market notabl china
follow impact inclus xalkori nrdl china
total revenu declin
compar declin
compar total intern revenu
declin compar
declin compar
oper growth due increas volum china
follow impact inclus xalkori nation reimburs
drug list nrdl china partial off-set volum declin
indic due competit pressur primarili across develop europ
us
total revenu inlyta increas
compar increas
compar
world-wide oper growth due increas demand
 result fda approv combin
inlyta pembrolizumab well inlyta bavencio first-lin
treatment patient advanc renal cell carcinoma impact
inclus inlyta nrdl china growth partial off-set
declin develop market due increas competit
total revenu increas
compar increas
compar total intern revenu
declin compar
decreas compar
total revenu eucrisa declin
compar decreas
compar total revenu us
decreas compar
decreas compar
 declin driven volum growth off-set
higher rebat unfavor channel mix addit one time
non-recurring favor rebat adjust
increas
increas
total revenu
eucrisa declin
decreas
total allianc revenu increas
compar increas
compar
total revenu increas
compar increas
compar total intern revenu
increas compar
increas compar
upjohn global primarili off-pat brand gener establish
medicin busi includ primarili off-pat solid oral dose
legaci brand well certain gener medicin
total revenu upjohn segment declin
compar decreas
compar total revenu
declin compar
decreas compar
total intern revenu decreas
compar decreas
compar
total upjohn revenu emerg market decreas
compar reflect oper
declin foreign exchang unfavor impact total upjohn
revenu emerg market oper decreas emerg
market primarili driven lipitor norvasc
total revenu emerg market rel flat reflect
oper growth off-set unfavor impact foreign exchang
total upjohn revenu emerg market oper increas
emerg market primarili driven lipitor norvasc celebrex
increas
increas
total revenu
decreas
declin
total revenu
lipitor decreas
remain flat
lyrica revenu declin compar
declin compar
total revenu declin
compar declin
compar total
intern revenu declin compar
declin
compar
declin due lower volum reflect wholesal
destock advanc anticip multi-sourc gener competit
expect begin juli instead began juli
oper declin intern mostli due gener
competit develop europ market price pressur across
intern market partial off-set increas volum japan
attribut growth oral dissolv tablet formul
increas volum russia
total revenu lipitor decreas
compar remain flat
compar total revenu declin
compar
declin compar
total intern revenu decreas
compar increas
compar
world-wide oper growth due increas demand china
driven invest geograph expans time
shipment vietnam
total revenu norvasc decreas
compar decreas
compar world-wide oper
growth due increas demand china driven
invest geograph expans
total revenu increas
compar increas
compar total intern revenu
decreas compar
decreas compar
total revenu celebrex increas
compar increas
compar
total revenu declin
compar decreas
compar
total intern revenu increas
compar increas
compar
world-wide oper growth due higher volum japan
china driven invest geograph expans
total revenu
norvasc decreas
decreas
total revenu
celebrex increas
increas
total revenu
viagra declin
decreas
total revenu viagra declin
compar decreas
compar total revenu
declin compar
decreas compar
total intern revenu decreas
compar decreas
compar
declin due loss exclus decemb
contribut lower volum price pressur oper
growth intern due increas demand china driven
invest geograph expans partial off-set price pressur
china lower volum across develop market
pfizer consum healthcar segment over-the-count medicin
busi juli combin gsk consum
healthcar busi form new consum healthcar joint ventur
upon close transact expect occur
differ fair valu equiti stake new compani
carri valu consum healthcar busi
account equiti stake new compani equity-
method invest asset liabil associ consum healthcar
busi reclassifi held sale consolid balanc sheet
june decemb
consum healthcar busi asset held sale report asset
held sale consum healthcar busi liabil held sale
report liabil held sale includ consum healthcar
busi tax asset liabil relat fulli dedic consum
total revenu
segment declin
decreas
total revenu consum healthcar segment declin
compar decreas
compar
total revenu declin compar
decreas
compar total intern revenu declin
compar decreas
compar
oper biopharmaceut busi emd serono
canada announc food drug
administr fda approv bavencio combin inlyta axitinib
firstlin treatment patient advanc renal cell carcinoma
lorbrena/lorviqua lorlatinib -- may announc
european commiss ec grant condit market author
lorviqua avail canada japan brand name
lorbrena monotherapi treatment adult patient
cancer nsclc whose diseas progress alectinib ceritinib
first tyrosin kinas inhibitor tki therapi crizotinib least
one tk
protein june advisori committe immun
practic acip center diseas control prevent cdc
vote revis pneumococc vaccin guidelin recommend
prevnar base share clinic decis make adult year
older immunocompromis condit
previous receiv prevnar
repres chang current cdc recommend routin
use among immunocompet adult age year older new
recommend mean decis vaccin made
individu level health care provid patient
acip recommend review approv cdc director
 depart human servic would
publish cdc morbid mortal weekli report prevnar
continu routin recommend adult
announc fda
biosimilar rituxan
rituximab
treatment adult
patient non-
leukemia
granulomatosi
polyangi
ruxienc rituximab-pvvr -- juli announc fda
approv ruxienc biosimilar rituximab treatment
adult patient non-hodgkin lymphoma chronic lymphocyt
leukemia granulomatosi polyangi microscop polyangi
talzenna talazoparib -- june announc ec
approv talzenna monotherapi treatment adult patient
germlin breast cancer suscept gene human
epiderm growth factor receptor local advanc metastat
breast cancer patient previous treat
anthracyclin and/or taxan neo adjuv local advanc
metastat set unless patient suitabl treatment
patient hormon receptor-posit breast cancer
treat prior endocrine-bas therapi consid unsuit
endocrine-bas therapi approv follow medicin approv
fda octob
juli fda
updat us
xeljanz includ two
warn well
chang indic
dose uc
vyndaqel/vyndamax tafamidi -- may announc
fda approv vyndaqel tafamidi meglumin vyndamax
tafamidi treatment cardiomyopathi wild-typ hereditari
transthyretin-medi amyloidosi attr-cm adult reduc
cardiovascular mortal cardiovascular-rel hospit
vyndaqel vyndamax two oral formul first-in-class
transthyretin stabil tafamidi first medicin approv
fda treat attr-cm recommend dosag either vyndaqel
mg oral once-daili taken four mg capsul vyndamax
mg oral once-daili taken singl capsul vyndamax develop
patient conveni vyndaqel vyndamax substitut per
juli fda updat prescrib inform
xeljanz includ two addit box warn well chang
indic dose uc updat base
fda review data post-market requir ra studi
june announc posit result oral shift phase
studi adult patient moder sever activ ra
patient achiev low diseas activ xeljanz extend
releas mg daili xeljanz xr plu methotrex
open-label run-in period random evalu
efficaci safeti xeljanz xr monotherapi withdraw
compar xeljanz xr continu
studi demonstr non-inferior withdraw xeljanz
xr compar xeljanz xr plu week measur
primari endpoint chang diseas activ score
random week end double-blind
withdraw phase week studi result present
late-break oral session annual european congress
announc
prac european
limit use xelanz
twice daili bid
patient increas risk
pulmonari embolisim
pe european
may announc pharmacovigil risk
assess committe prac european medicin agenc
ema issu recommend limit use xeljanz mg twice
daili bid patient increas risk pulmonari embol pe
european union eu recommend
incorpor updat eu product label xeljanz
provision prac undertak review avail evid
safeti efficaci xeljanz
review result observ increas risk pe
tofacitinib mg bid on-going fda post-market requir
studi individu ra one underli
cardiovascular risk factor specif recommend
tofacitinib mg bid prescrib patient
high risk pe addit patient alreadi take mg bid
high risk pe switch altern treatment
eu tofacitinib mg bid approv dose patient uc
approv dose patient moder sever ra
activ
review carri prac committe respons
evalu safeti issu human medicin make
set recommend request ec prac
recommend forward committe
medicin product human use final stage review
procedur adopt ec legal bind decis
applic eu member state
zirabev bevacizumab-bvzr -- june announc fda
approv zirabev biosimilar treatment five type
cancer metastat colorect cancer unresect local advanc
recurr metastat nsclc recurr glioblastoma metastat rcc
persist recurr metastat cervic cancer
comprehens updat develop pipelin publish today
avail www pfizer com/science/drug-product-pipelin
includ overview research list compound
develop target indic phase develop well
mechan action candid phase candid
phase registr
result phase pivot studi jade evalu efficaci
safeti investig oral janu kinas inhibitor
abrocitinib patient age older moder sever ad jade
random double-blind placebo-control parallel-group
studi design evalu efficaci safeti two dose mg
mg daili abrocitinib monotherapi week
top-lin result show week percentag patient achiev
co-primari efficaci endpoint key secondari endpoint
either dose abrocitinib statist significantli higher placebo
addit result demonstr respons treatment statist
signific number patient first two four week follow
first dose safeti result show dose abrocitinib well-
toler unexpect safeti event
case major advers cardiovascular event malign venou
thromboembol includ deep vein thrombosi pe observ
jade studi discontinu rate due advers event
low treatment arm mg mg
respect compar placebo
glasdegib -- may ema valid review
market author applic glasdegib propos
treatment acut myeloid leukemia adult patient
candid standard induct chemotherapi
line result phase
evalu
efficaci safeti
inhibitor abroctinib
patient age
older moder
clinic data pf-
therapi potenti
dystrophi dmd
-- june present initi phase clinic data
investig gene therapi potenti treat duchenn
muscular dystrophi dmd annual parent project muscular
primari endpoint on-going phase studi assess safeti
toler investig gene therapi secondari endpoint
clinic studi includ measur express mini-dystrophin
distribut within muscl fiber immunofluoresc concentr
liquid chromatographi mass spectrometri
aim enrol approxim boy dmd ambulatori
age date studi particip rang age
year receiv one-tim intraven dose either
 vector genomes/kilogram vg/kg vg/kg quantifi
use invert termin repeat-bas quantit polymeras chain
continu collect data on-going open-label studi boy
dmd also plan stage global random placebo-
control phase studi studi expect begin first half
commercial-scal manufactur process use multipl
liter bioreactor anticip phase studi intend leverag
learn on-going phase studi order inform pfizer
decis regard optim dose assay method administr
concomit medic particip select safeti monitor
announc updat result phase alta studi
evalu investig gene therapi sever hemophilia
data show gener well-toler demonstr
dosedepend increas factor viii fviii activ level first two
patient treat vg/kg dose rapidli achiev normal level
fviii activ measur use chromogen assay report
bleed event respons continu durabl long
week extent follow-up
two patient recent treat vg/kg dose level
demonstr fviii activ kinet appear consist first two
patient treat dose cohort similar earli time point data
patient treat present oral present
juli xxvii congress intern societi thrombosi
haemostasi develop part global collabor
sangamo
base assess total subcutan sc tanezumab
data initi discuss fda second-quart
compani lilli decid pursu
regulatori submiss tanezumab mg sc patient
moderate-to-sever osteoarthr oa expect file
fda fourth-quart earli follow potenti
regulatori file eu japan
time regulatori submiss plan tanezumab
mg sc dose oa patient moderate-to-sever chronic low
back pain clbp lilli intend maintain open dialogu
regulatori author potenti futur regulatori pathway
juli lilli announc top-lin result phase
studi evalu long-term safeti efficaci tanezumab rel
nonsteroid anti-inflammatori drug celecoxib japanes
patient moderate-to-sever clbp studi
patient random receiv tanezumab mg sc mg
sc everi eight week celecoxib twice daili treatment period
week studi also includ safeti follow-up period
total week observ
juli
result phase
studi evalu
long-term safeti
efficaci tanezumab
rel
celecoxib japanes
patient moderate-
global gener
definit agreement
combin upjohn
creat new
patient enrol requir stabl regimen
celecoxib experienc benefit treatment primari
object studi evalu long-term safeti
tanezumab measur outcom relat gener sympathet
peripher nervou system joint safeti
preliminari data show overal advers event profil
tanezumab gener consist previous report studi
tanezumab clbp rate composit joint safeti event
consist adjud outcom rapidli progress osteoarthr
rpoa type type subchondr insuffici fractur
osteonecrosi patholog fractur observ
period tanezumab treatment arm
incid rpoa observ tanezumab arm
one case type type subchondr insuffici
fractur observ tanezumab-tr patient
event osteonecrosi patholog fractur studi
one patient studi take tanezumab mg underw total joint
replac detail result studi submit
regulatori author part routin safeti updat
share futur scientif forum
global gener specialti pharmaceut compani
announc definit agreement combin upjohn creat
new global pharmaceut compani term agreement
structur all-stock revers morri trust transact
sharehold would sharehold would
board director unanim approv
transact compani anticip transact close mid-
subject customari close condit includ receipt regulatori
approv approv sharehold
juli announc success complet acquisit
privat held clinical-stag biotechnolog compani therachon
term transact acquir therachon million
addit million addit payment conting
achiev key mileston develop commerci
investig medicin treatment achondroplasia
genet condit common form short-limb dwarfism
current approv treatment option achondroplasia
june announc enter definit merger
agreement acquir array commerci stage biopharmaceut compani
focus discoveri develop commerci target
small molecul medicin treat cancer diseas high unmet
agre acquir array per share cash total enterpris
valu approxim billion array portfolio includ approv
combin use braftovi encorafenib mektovi binimetinib
treatment mutant unresect metastat
melanoma combin therapi signific potenti long-
term growth via expans addit area unmet need
current investig clinic trial across sever solid tumor
indic includ phase beacon trial braf-mut metastat
announc success
complet
acquisit
upon close transact expect occur third-quart
array employe join continu locat
cambridg massachusett morrisvil north carolina well
boulder colorado becom part pfizer oncolog network
addit la jolla california pearl river new york
expect financ major transact debt
balanc exist cash transact expect dilut
pfizer adjust dilut approxim dilut
neutral accret begin
addit accret growth anticip thereaft
expect financ
major
transact debt
balanc
rang
adjust sale
incom
effect tax rate adjust incom
decreas
pfizer revenu decreas remain
rel flat sale decreas
decreas decreas cost sale
due favor impact foreign exchang favor impact
hedg activ inter-company inventori partial off-set
unfavor chang product mix
basic ep increas compar
dilut ep increas compar
basic ep increas
compar dilut ep increas
compar
biopharma revenu increas increas
total revenu upjohn segment declin
decreas
continu invest provid potenti futur sourc revenu
develop new product well addit use
in-lin allianc product
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas ttm basi compar
oper margin increas ttm basi compar
net margin increas ttm basi compar
revenu growth y/i ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc octob
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale pfizer inc octob
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset pfizer inc octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer annual itemsquarterli item pfizer inc octob
balanc item
outstand equival market debt common prefer purchas properti plant purchas purchas sale repurchas net issuanc net chang capit free inc octob
current price-to-earnings ratio fallen due declin stock
price quarter price-to-earnings fallen averag price-to-earnings expect
forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit world wellington manag compani jp morgan america price row associ inc geod capit manag llc northern trust corpor top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf washington mutual investor fund vanguard institut fund-institut fidel incom fund america inc ishar vanguard -valu american balanc competit
develop announc posit preliminari result proof-of-concept phase studi pneumococc conjug vaccin candid investig prevent invas diseas otiti media infant septemb today announc today posit preliminari result follow administr three dose four-dos seri proof-of-concept phase studi assess safeti immunogen pneumococc conjug vaccin candid investig prevent invas diseas otiti media caus streptococcu pneumonia serotyp contain vaccin healthi infant candid includ serotyp contain prevnar pneumococc conjug vaccin plu seven addit serotyp fda grant xtandi enzalutamid applic prioriti review treatment men metastat hormone-sensit prostat canceraugust pharma inc inc announc today fda accept review file supplement new drug applic xtandi add indic treatment men metastat hormone-sensit prostat cancer mhspc applic also grant prioriti review design given applic drug approv may offer signific improv safeti effect treatment diagnosi prevent seriou condit compar standard applic xtandi current indic treatment patient castration-resist prostat cancer invest half billion dollar advanc state-of-the-art gene therapi facil sanford north carolinaaugust announc today addit half billion dollar invest constructionof state-of-the-art gene therapi manufactur facil sanford north carolina facil anticip support continu invest gene therapi research develop similar chapel hill kit north carolina research develop site facil would expand compani presenc north carolina current colleagu includ sanford expand facil project add approxim new job complet acquisit array biopharma juli today announc success complet acquisit array biopharma inc advanc breakthrough scienc discoveri develop commerci target small molecul medicin treat cancer diseas high unmet need inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
roa roi roe
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc octob
consensu view analyst trend stock
compar
 average
forward price-to-earnings multipl
compar
 average
pfe avgfive-year growth forecast usdgrowth high day day day estim comparisonpfeindustri avg avgprice/earn yield inc octob
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim next
qtr
averag revenu estim
current qtr sept
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr pfizer inc octob
price target summarycrispidea stanley maintainsequ weight stanley downgradeoverweightequ weight america america maintainsbuybuy suiss upgradeneutraloutperform upgradeneutraloutperform recommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext inc octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price dip august later show upward trend current trade
stock price lost period
stock price volatil till juli later dip august
rang stock stock lost year
stock price shown upward trend surg novemb
stock gave return past
pfizer revenu decreas quarter oper growth driven
oper growth pfizer biopharmaceut group recommend hold rate due
declin revenu due biosimilar competit product downgrad tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
